Submission supported by positive results from global, Phase 3 4WHIM clinical trial;U.S. regulatory approval in WHIM syndrome granted in ...

X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...

A set of chameleon-like immune cells could be contributing to severe asthma in some patients. Intermediate group 2 innate ...

DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...

Researchers at McMaster University have made an important discovery in the field of asthma research, identifying a new ...

Researchers at McMaster University have made an important discovery in the field of asthma research, identifying a new ...

A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

Tumor heterogeneity remains a formidable obstacle in targeted cancer therapy, often leading to suboptimal treatment outcomes. This study presents an innovative approach that harnesses controlled ...

Inflammation often gets a bad reputation, frequently linked to deadly conditions like heart disease, stroke, dementia, and cancer. But is inflammation the enemy it's made out to be? Let's break it ...